Radhakrishna Pillai M, Sreevidya S, Pollock Brad H, Jayaprakash P G, Herman Brian
Division of Laboratory Medicine, Regional Cancer Centre, Thiruvananthapuram, India.
Gynecol Oncol. 2002 Dec;87(3):268-73. doi: 10.1006/gyno.2002.6835.
Human papillomavirus type 16 is a causative factor for development of cervical cancer. The E6 and E7 genes of HPV 16 are critical to the process of immortalization and transformation of host cells. Recent reports suggest that variants of these two genes may contribute to the risk of malignant progression of cancer in the uterine cervix. However, no data exist on sequence variations of HPV 16 E6 and E7 genes that may exist in India. Therefore, we examined intratype variations in the E6 and E7 viral genes in DNA isolated from HPV 16-positive cervical scrapes and biopsies.
The open reading frames of the E6 and E7 genes were amplified by PCR and then directly sequenced by the fluorescent dye dideoxy termination method.Results. In addition to the prototype E6 gene sequence, five sets of mutations of the E6 gene were identified. The European prototype (350T) was detected in 9.1% of the study group while the European variant (350G) was seen in 28% of patients. The remaining variants (a combination of the 350G mutation with 335T, 145T, or 419G) were significantly associated with cases compared to controls. The 350G + 145T variant was found at much higher incidence in cases in younger women, suggesting that this variant may be associated with aggressive tumor behavior. Interestingly the 350G + 419G combination was found only in controls. There was no significant association between the four genotypes of E7 and any stage of tumor progression or age.
The results indicate that specific mutations in the E6 gene are found in young Indian women with high-grade squamous intraepithelial lesions and invasive cancer, suggesting that these mutations represent more oncogenically active HPV 16. Whether this increased oncogenecity is due to differences in p53 inactivation, ineffective keratinocyte differentiation, and/or altered response to the immune system by these oncogenic E6 mutants remains to be clarified.
人乳头瘤病毒16型是宫颈癌发生的一个致病因素。HPV 16的E6和E7基因对于宿主细胞的永生化和转化过程至关重要。最近的报告表明,这两个基因的变异可能会增加子宫颈癌恶性进展的风险。然而,关于印度可能存在的HPV 16 E6和E7基因序列变异尚无数据。因此,我们检测了从HPV 16阳性宫颈刮片和活检组织中分离的DNA中E6和E7病毒基因的型内变异。
通过PCR扩增E6和E7基因的开放阅读框,然后用荧光染料双脱氧终止法直接测序。结果。除了原型E6基因序列外,还鉴定出五组E6基因突变。在9.1%的研究组中检测到欧洲原型(350T),而在28%的患者中发现了欧洲变体(350G)。其余变体(350G突变与335T、145T或419G的组合)与对照组相比,与病例有显著关联。在年轻女性病例中发现350G + 145T变体的发生率要高得多,表明该变体可能与侵袭性肿瘤行为有关。有趣的是,350G + 419G组合仅在对照组中发现。E7的四种基因型与肿瘤进展的任何阶段或年龄之间均无显著关联。
结果表明,在患有高级别鳞状上皮内病变和浸润性癌的年轻印度女性中发现了E6基因的特定突变,表明这些突变代表了具有更高致癌活性的HPV 16。这种致癌性增加是否是由于这些致癌性E6突变体在p53失活、角质形成细胞分化无效和/或对免疫系统的反应改变方面的差异,仍有待阐明。